Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis
Cancer Cell · 2023-04 · 41 (4) · 740-756.e10
DOI: 10.1016/j.ccell.2023.03.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2023-04. Verfasst von Wei Zhou und 20 weiteren Autor:innen. Beteiligte Einrichtung: Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Carcinoma. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Wistar Institute, National Institutes of Health.
Abstract (Originalsprache)
ARID1A, encoding a subunit of the SWI/SNF complex, is mutated in ∼50% of clear cell ovarian carcinoma (OCCC) cases. Here we show that inhibition of the mevalonate pathway synergizes with immune checkpoint blockade (ICB) by driving inflammasome-regulated immunomodulating pyroptosis in ARID1A-inactivated OCCCs. SWI/SNF inactivation downregulates the rate-limiting enzymes in the mevalonate pathway such as HMGCR and HMGCS1, which creates a dependence on the residual activity of the pathway in ARID1A-inactivated cells. Inhibitors of the mevalonate pathway such as simvastatin suppresses the growth of ARID1A mutant, but not wild-type, OCCCs. In addition, simvastatin synergizes with anti-PD-L1 antibody in a genetic OCCC mouse model driven by conditional Arid1a inactivation and in a humanized immunocompetent ARID1A mutant patient-derived OCCC mouse model. Our data indicate that inhibition of the mevalonate pathway simultaneously suppresses tumor cell growth and boosts antitumor immunity by promoting pyroptosis, which synergizes with ICB in suppressing ARID1A-mutated cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA.
- Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
- Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA; Department of Pharmacy and Biotechnology, University of Bologna, 40126, Bologna, Italy.
- Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA.
- Bioinformatics Facility, The Wistar Institute, Philadelphia, PA 19104, USA.
- Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA 19104, USA.
Förderung
- NCI NIH HHS
- Wistar Institute
- National Institutes of Health
- Cancer Prevention and Research Institute of Texas
- Congressionally Directed Medical Research Programs
- University of Texas MD Anderson Cancer Center
- U.S. Department of Defense
- The Philadelphia Foundation
Zitieren
APA
Zhou, W., Liu, H., Yuan, Z., Zundell, J., Towers, M., Lin, J., Lombardi, S., Nie, H., Murphy, B., Yang, T., Wang, C., Liao, L., Goldman, A. R., Kannan, T., Kossenkov, A. V., Drapkin, R., Montaner, L. J., Claiborne, D. T., Zhang, N., …, & Zhang, R. (2023). Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell, 41(4), 740-756.e10. https://doi.org/10.1016/j.ccell.2023.03.002
Vancouver
Zhou W, Liu H, Yuan Z, Zundell J, Towers M, Lin J, et al. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell. 2023;41(4):740-756.e10. doi:10.1016/j.ccell.2023.03.002
BibTeX
@article{Zhou2023,
author = {Zhou, Wei and Liu, Heng and Yuan, Zhe and Zundell, Joseph and Towers, Martina and Lin, Jianhuang and Lombardi, Simona and Nie, Hao and Murphy, Brennah and Yang, Tyler and Wang, Chen and Liao, Liping and Goldman, Aaron R and Kannan, Toshitha and Kossenkov, Andrew V and Drapkin, Ronny and Montaner, Luis J and Claiborne, Daniel T and Zhang, Nan and Wu, Shuai and Zhang, Rugang},
title = {Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis},
journal = {Cancer Cell},
year = {2023},
volume = {41},
number = {4},
pages = {740--756.e10},
doi = {10.1016/j.ccell.2023.03.002}
}
EUVIMED